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INTRODUCTION
Complete, long-term adherence to combination
antiretroviral regimens is necessary to avoid treat-
ment failure and the selection of drug-resistant
variants in HIV patients. For this reason, due to
the role of dose interval and pill burden as ad-
herence barriers (Stone et al., 2004), simplifica-
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tion regimens with once-daily, low pill burden
regimens may favor patient compliance with an-
tiretroviral therapy (Trotta et al., 2002; Trotta et
al., 2003).
Among HIV protease inhibitors (PIs), atazanavir
(ATV) is the only one licensed for once-daily use
and has a more favorable impact on lipid profile
compared with lopinavir/ritonavir (LPV/r)
(Johnson et al., 2006; Molina et al., 2008). This is
particularly important when managing patients
with high cardiovascular risk, in view of the as-
sociation between myocardial infarction and HIV
replication, exposure to antiretrovirals (PIs, aba-
cavir, didanosine), and aging of HIV-infected pa-
tients (DAD Study Group, 2007; DAD Study
Group, 2008).
Switches from lopinavir/ritonavir (LPV/r) to either atazanavir/ritonavir (ATV/r) or unboosted ATV (ATV) are increas-
ingly common in clinical practice, but data on outcome comparison between these two simplification strategies are
very limited. Methods. Multicenter, observational, retrospective study. Data were collected from five Italian clinics. The
objective of the study was to investigate the utcome of LPV/r simplification with ATV/r or ATV and to identify factors
predicting virological rebound. Patients who switched from LPV/r to ATV/r or ATV with an HIV-RNA value<50
copies/mL at the time of switch and with at least one follow-up visit were included. 
We evaluated 468 patients (74.1% males), followed for a median (Q1-Q3) of 547 (305-788) days: 380 (81%) and 88 (19%)
switched to ATV/r and to ATV, respectively. Virological rebound was detected in 78/468 (16.7%, 95% CI: 13.6 -20.3)
patients [16/88 (18.2%, 95% CI: 11.4 -27.6) switched to ATV and 62/380 (16.3%, 95% CI: 12.9 -20.4) to ATV/r (p=0.638)]. 
Virological rebound was more frequent in patients who started LPV/r with HIV-RNA >30000 copies/mL (28% vs 6%,
p=0.014). 
Replacing lopinavir/r with ATV or ATV/r yielded similar rates of virological rebound. Viral load at the initiation of
lopinavir/r may be useful in driving the choice between ATV/r and ATV.
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Due to its convenience and tolerability, a change
from a LPV/r-based regimen to either
atazanavir/ritonavir (ATV/r) - or unboosted ATV
(ATV) - based regimens is increasingly common
in clinical practice despite a lack of clear data in-
dicating which strategy is preferable (ATV/r or
ATV) according to the patient’s medical history.
Replacing LPV/r with ATV- or ATV/r-based regi-
mens in HIV-infected patients with undetectable
viremia has been investigated in two randomized
studies (Mallolas et al., 2007; Soriano et al., 2008),
but neither study managed to define which strat-
egy is preferable. The present study investigated
the outcome of LPV/r simplification with boost-
ed or unboosted atazanavir, aiming also to iden-
tify factors predicting virological rebound.
MATERIALS AND METHODS 
This was a multicenter, observational, retrospec-
tive study. Data were collected from the databas-
es of five leading Italian Infectious Diseases
Clinics. Demographic and clinical characteristics
as well as laboratory parameters including lipidic
and glucidic profile were regularly collected at
different times of follow-up; HDL-cholesterol,
LDL-cholesterol, and the use of lipid-lowering
agents were not regularly recorded in the data-
bases.
All patients who switched from a LPV/r- to an
ATV/r- or to an ATV-based regimen were includ-
ed in this analysis if they met both of the follow-
ing criteria: HIV-RNA <50 copies/mL at the time
of medication switch, and at least one follow-up
visit after switch to ATV or ATV/r.
Patients were followed until discontinuation of
treatment with ATV, a switch from ATV/r to ATV
or vice versa, or until data freezing (June 30, 2007
while on ATV), whichever occurred first.
The primary objective of this study was to evalu-
ate the proportion of virological rebound in viro-
logically suppressed patients switched from a
LPV/r to an ATV or an ATV/r-containing regimen.
The secondary objectives were to assess if these
two strategies led to differences in CD4 changes
as well as in lipid and glucose profiles. The pri-
mary end-point (outcome of the study) was the
proportion of patients with HIV-RNA values of
>50 copies/mL (confirmed twice) at data censor-
ing on ATV based regimen. Secondary end-points
were absolute and relative changes from baseline
in CD4+ cell counts and in the laboratory tests
concerning metabolic lipidic profile. HIV-RNA
was assessed in each center by means of b-DNA
(Versant RNA 3.0, bayer Puteaux Cedex, France)
or Amplicor (Monitor test 1.5, Roche Diagnostics,
Manheim, Germany). The detectability ratio was
defined as the ratio between the number of de-
tectable (>50 copies/mL) viral loads and the num-
ber of viral loads tested prior to the switch to
ATV-based regimen. 
Statistical analysis
Results were described as median (Q1-Q3) for con-
tinuous variables and frequency (%) for categori-
cal variables. The Mann-Whitney rank sum test
was used to compare independent distribution val-
ues of continuous variables, the Wilcoxon sign
rank test was used to assess significant changes
from baseline, and the Chi-square or Fisher’s ex-
act test were employed to assess significant rela-
tionships between categorical variables. 
The probability of virological rebound was esti-
mated by the Kaplan-Meier method. The multi-
variable analysis was performed applying the Cox
proportional hazard regression to identify inde-
pendent predictors of virological rebound. Time
zero for the analysis was the date of the switch to
ATV; the time to virological rebound was defined
as the time to the occurrence of the first con-
firmed detectable viremia (HIV-RNA values of
>50 copies/mL) or the most recent clinical fol-
low-up evaluation while on ATV. The propor-
tional hazards assumption was verified in rela-
tion to the covariates included in the model.
Hazard ratios were estimated with their corre-
sponding 95% confidence intervals (CI). Two dif-
ferent models were evaluated in relation to the
set of the included covariates. The first model
considered all covariates with available data for
all patients of the five participating centers; the
second model included two additional covariates
(HIV-RNA at LPV/r start and the detectability ra-
tio), available only in a subgroup of patients.
Given the exclusion of a consistent number of ob-
servations for this second analysis, the baseline
characteristics between the excluded and the in-
cluded patients were compared. All the statisti-
cal tests were two-sided at the 5% level, and per-
formed using SAS Software (SAS Institute), re-
lease 9.2.
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RESULTS
Four hundred sixty-eight patients (74.1% males)
fulfilled the inclusion criteria. Three hundred and
eighty (81%) and 88 (19%) were switched to an
ATV/r-containing regimen and to an ATV-con-
taining regimen, respectively. The baseline char-
acteristics of the patients included are listed in
Table 1. The drugs most frequently used at base-
line (in combination with LPV/r) were: lamivu-
dine (64%), tenofovir (42%), didanosine (29%),
zidovudine (28%), and stavudine (14%). The
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TAbLE 1 - Baseline characteristics of 468 patients with undetectable viral load switched 
from lopinavir/ritonavir to boosted or unboosted atazanavir.
Switched to
All N=468 ATV/r N=380 ATV N=88 P-value 
(81%) (19%) (ATV/r vs. uATV)
Age (years) (median (IQR)) 44.5 (40.9-49.7) 44.6 (41.0-49.9) 44.3 (40.7-48.5) 0.548
Males [n (%)] 347 (74.1 %) 285 (75.0%) 62 (70.4%) 0.418
Previous AIDS diagnosis (n (%)) 140 (29.9%) 112 (29.5%) 28 (31.8%) 0.699
HCVAb+ [n (%)] 111 (38.0%) 82 (36.8%) 29 (42.0%) 0.479
HbsAg+ [n (%)] 20 (7.0%) 16 (7.1%) 4 (6.3%) 0.827
Nadir CD4+ [median (IQR)] 159 (62-246) 156 (57-247) 168 (85-243) 0.664
CD4+/µL [median (IQR)] 433 (302-620) 447 (317-624) 399 (273-561) 0.071
HIV-RNA at LPV/r start (log10 copies/mL) 4.48 (3.62-5.0) 4.58 (3.85-5.04) 4.1 (3.3-4.8) 0.011
<=30000 copies/mL 125 (26.7%) 91 (24.0%) 34 (38.6%) 0.017
>30000 copies/mL 127 (27.1%) 109 (28.7%) 18 (20.5%)
Unknown 216 (46.2%) 180 (47.4%) 36 (40.9%)
Duration of LPV/r (days) [median (IQR)] 520 (305-897) 522 (330-905) 514 (238-824) 0.183
Any change in the backbone at switch 235 (50.2%) 199 (52.4%) 36 (40.9%) 0.059
to ATV [n (%)]
Change in nucleoside analogues in the 231 (50.6%) 195 (51.3%) 36 (40.9%) 0.097
regimen at switch to ATV [n (%)]
Use of tenofovir with ATV [n (%)] 263 (56.2%) 240 (63.2%) 23 (26.1%) <0.0001
Switch to tenofovir 95 (20.3%) 88 (23.2%) 7 (8.0%)
Use of thymidine analogues [n (%)] 89 (19.0%) 58 (15.3%) 31 (35.2%) <0.0001
No TA with LPV/r and ATV 261 (55.8%) 221 (58.2%) 40 (45.5%)
No TA with LPV/r but with ATV 9 (1.9%) 5 (1.3%) 4 (4.5%) <0.0001
TA with LPV/r and not with ATV 118 (25.2%) 101 (26.6%) 17 (19.3%)
TA with LPV/r and ATV 80 (17.1%) 53 (14.0%) 27 (30.7%)
Total cholesterol (mg/dL) [median (IQR)] 215 (172-248) 213 (173-248) 216 (167-243) 0.832
Triglycerides (mg/dL) [median (IQR)] 213 (139-336) 217 (137-333) 198 (143-338) 0.616
Glucose (mg/dl) [median (IQR)] 91 (82-100) 91 (82-100) 88 (80-99) 0.096
ATV: unboosted atazanavir; ATV/r: boosted atazanavir; LPV/r: lopinavir/ritonavir
drugs used most frequently in combination with
ATV were: lamivudine (67%), tenofovir (67%),
emtricitabine (29%), didanosine (22%), abacavir
(20%) and zidovudine (14%). Thirty patients
(6.4%) switched to an ATV-containing regimen
not including any NRTIs (8 patients were on
ATV/r monotherapy and 5 patients on ATV
monotherapy). HIV-RNA at LPV/r start was high-
er among patients switched to ATV/r (p=0.011)
and the concomitant use of tenofovir was more
frequent among these patients (ATV/r: 63.2%;
ATV: 26.1%, p<0.0001) whereas the concomitant
use of thymidine analogues was more frequent
among patients switched to ATV (ATV/r: 15.3%;
ATV: 35.2%, p<0.0001). The median (IQR) dura-
tion of treatment with ATV was 547 (305-788)
days, with no differences between the two groups:
555 (322-792) days for patients switched to ATV/r
vs 531 (196-755) days for those switched to ATV
(p=0.199). During follow-up, 37 (9.7%) patients
switched from ATV/r to uATV and 7 (8%)
switched from ATV to ATV/r; all patients but 3
switched their initial ATV-containing regimen
when they had undetectable viremia. 
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FIGURE 1 - Panel A - Probability of being free from viral rebound (HIV-RNA >50 copies/mL) according
to switch to unboosted (ATV) or boosted atazanavir (ATV/r) (Kaplan-Meier curves). Panel B - Probability
of being free from viral rebound (HIV-RNA >50 copies/mL) according to switch to unboosted or boosted
atazanavir and use of TDF (Kaplan-Meier curves). Panel C - Probability of being free from viral rebound
(HIV-RNA >50 copies/mL) according to switch to unboosted or boosted atazanavir and use of thymidine
analogues (Kaplan-Meier curves). Panel D - Probability of being free from viral rebound (HIV-RNA >50
copies/mL) according to switch to unboosted or boosted atazanavir and HIV-RNA at LPV/r start (<=30000
vs >30000 copies/mL) (Kaplan-Meier curves).
At the end of follow-up, virological rebound was
detected in 78/468 (16.7%, 95% CI: 13.6 -20.3) pa-
tients: 16/88 (18.2%, 95% CI: 11.4 -27.6) were
switched from LVP/r to an ATV-containing regi-
men and 62/380 (16.3%, 95% CI: 12.9 -20.4) were
switched from LPV/r to an ATV/r-containing reg-
imen (p=0.638). The probability of being free
from virological rebound was not statistically dif-
ferent between the two groups (p=0.708, Figure 1,
Panel A).
The univariable analysis both on frequencies of
virological rebound or on the probabilities of be-
ing free of virological rebound was evaluated ac-
cording to the use of tenofovir, the use of thymi-
dine analogues and in relation to the viral load
data at LPV/r initiation.
For tenofovir, the frequency of virological re-
bound was similar between patients using this
drug or not (No use of TDF: 33/205=16.1%; Use
of TDF: 45/263=17.1%, p=0.804). Virological re-
bound occurrence was similarly frequent both in
patients who switched from LVP/r to an ATV-con-
taining regimen (No use of TDF: 13/65 (20.0%);
Use of TDF: 3/23 (13.0%), p=0.546) and in those
who switched to an ATV/r-containing regimen
(No use of TDF: 20/140 (14.3%); Use of TDF:
42/240 (17.5%), p=0.473). Even when consider-
ing separately patients using tenofovir or not, no
differences in the proportions of virological re-
bound were detected between patients who
switched to ATV and those who switched to
ATV/r (No use of TDF: ATV=20% vs
ATV/r=14.3%, p=0.313; Use of TDF: ATV=13% vs
ATV/r=17.5%, p=0.775). The probability of being
free from virological rebound according to the
use of tenofovir in combination with atazanavir
was not statistically different (p=0.814) as shown
in Figure 1, (Panel b). The probability was simi-
lar also when considering the type of ATV-regi-
men:no differences were detected among the four
groups (p=0.834) or within the ATV group
(p=0.587) or within the ATV/r group (p=0.510).
In addition, when considering separately patients
using tenofovir or not, the probability of being
free from virological rebound did not differ be-
tween patients who switched to an ATV- rather
than an ATV/r-containing regimen (No use of
TDF: p=0.401; Use of TDF: p=0.707).
The analysis in relation to the use of thymidine
analogues showed that the frequency of virolog-
ical rebound was not significantly different (No
use of thymidine analogues: 57/379=15%; Use of
thymidine analogues: 21/89=23.6%; p=0.058). The
frequency of virological rebound was also similar
between patients using thymidine analogues or
not, both in patients who switched to an ATV-
containing regimen (No use of thymidine ana-
logues: 8/57 (14.0%); Use of thymidine analogues:
8/31 (26.0%), p=0.247) and in those who switched
to an ATV/r-containing regimen (No use of thymi-
dine analogues: 49/322 (15.2%); Use of thymidine
analogues: 13/58 (22.4%), p=0.179). Even when
considering separately patients using thymidine
analogues or not, no differences in the propor-
tions of virological rebound were detected be-
tween patients who switched to ATV and those
who switched to ATV/r (No use of thymidine ana-
logues: ATV= 14% vs ATV/r=15%, p=0.999; Use
of thymidine analogues: ATV=26% vs
ATV/r=22%, p=0.796). The probability of being
free from virological rebound according to the
use of thymidine analogues in combination with
atazanavir was not statistically different (p=0.087)
as shown in Figure 1 (Panel C). The probability
was similar also when considering the type of
ATV-regimen (overall effect: p=0.392; ATV group:
p=0.269; ATV/r group: p=0.205). In addition,
when considering separately patients using or not
using thymidine analogues, the probability of be-
ing free from virological rebound was not differ-
ent between patients who switched to an ATV-
rather than to an ATV/r-containing regimen, (use
of thymidine analogues: p=0.810; no use of thymi-
dine analogues: p=0.879). 
Then the analysis was restricted to those patients
with available viral load data at LPV/r initiation
stratified according to the median value (30000
copies/mL =4.4771213 log10). The frequency of
virological rebound was not significantly different
although it tended to occur more frequently
among patients who started LPV/r with HIV-RNA
values above or below 30000 copies/ml th HIV-
RNA values of >30000 copies/mL (21/127=16.5%
vs 11/125=8.8%, p=0.088). In addition, although
the difference in virological rebound was not sta-
tistically different between patients who switched
to ATV or to ATV/r within each virological strata,
in patients with HIV-RNA values of >30000
copies/ml at LPV/r start, virological rebound was
roughly twofold more frequent in those who
switched to ATV than in those who switched to
ATV/r (HIV-RNA >30000 copies/ml: ATV=28% vs
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ATV/r=15%, p=0.178; HIV-RNA <=30000
copies/ml: ATV=6% vs ATV/r=10%, p=0.726).
Among patients switched to an ATV-containing
regimen, virological rebound was more frequent
in those who started LPV/r with HIV-RNA values
of >30000 copies/mL (28% vs 6%, p=0.041)
whereas no difference was observed among pa-
tients switched to ATV/r (15% vs 10%, p=0.392). 
The probability of being free from virological re-
bound, according to strata of viral load at LPV/r
initiation and ATV-regimen, is shown in Figure 1
(Panel D): overall no statistical difference was
found among the four groups (p=0.079) or among
patients switched to an ATV/r-containing regi-
men (p=0.226). On the contrary, the probability
of being free from virological rebound was sta-
tistically different between the two HIV-RNA stra-
ta (p=0.014) when considering patients switched
to an ATV-containing regimen but not among pa-
tients switched to an ATV/r-containing regimen
(p=0.247). In addition, when considering sepa-
rately patients above or below 30000 copies/ml,
the probability of being free from virological re-
bound was not different between patients who
switched to an ATV- rather than to an ATV/r-con-
taining regimen (HIV-RNA> 30000 copies/ml:
p=0.178; HIV-RNA <=30000 copies/ml: p=0.397). 
At multivariable analysis, after adjustment for
age, gender, nadir CD4+ and baseline CD4+, du-
ration of treatment with LPV/r, switch to ATV or
ATV/r, change in the nucleoside analogues in the
regimen, use of tenofovir, patients using thymi-
dine analogues in the ATV- based regimen were
more likely to have virological rebound during
follow-up [HR=1.862, 95% CI; 1.036-3.347,
p=0.038 (Table 2 - Model 1)]. Notably, switching
to ATV rather than to ATV/r did not independ-
ently predict virological failure. 
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TAbLE 2 - Multivariable analysis: adjusted hazard ratios for viral rebound estimated by Cox proportional
hazard regression model.
Model 1 (N=453) Model 2 (N=158)
Covariate HR 95% CI (HR) P-value HR 95% CI (HR) P-value
Age (per 1-year increment) 0.976 0.949-1.004 0.096 0.996 0.932-1.064 0.898
Gender (M vs F) 0.989 0.582-1.680 0.967 0.518 0.166-1.612 0.256
Nadir CD4 (per 1-cell/mL increment) 0.999 0.997-1.001 0.346 0.996 0.991-1.000 0.053
baseline CD4 (per 1-cell increment) 1.001 1.000-1.002 0.221 1.001 0.998-1.003 0.503
HIV-RNA at LPV/r start >30000 vs - - - 3.615 1.499-8.717 0.004
<=30000 copies/mL
Detectability ratio (# detectable VLs/ # - - - 12.998 1.299-130.042 0.029
tested VLs prior to ATV±r) (per 1-unit 
increment)
LPV/r duration (per 1-day increment) 1.000 0.999-1.000 0.316 1.00 0.999-1.001 0.976
Switch to unboosted vs boosted ATV 0.859 0.472-1.562 0.618 1.536 0.588-4.012 0.381
Change in nucleoside analogues in the 1.414 0.867-2.306 0.166 1.087 0.451-2.624 0.852
regimen at switch to ATV (Yes vs No)
Use of thymidine analogues with ATV 1.862 1.036-3.347 0.038 3.462 1.164-10.295 0.026
(Yes vs No) 
Use of tenofovir with ATV (Yes vs No) 1.139 0.677-1.914 0.624 1.252 0.454-3.453 0.664
ATV: unboosted atazanavir; ATV/r: boosted atazanavir; LPV/r: lopinavir/ritonavir; VL: viral load.
The increased risk of virological rebound associ-
ated with the use of thymidine analogues was
confirmed (HR=3.462, 95% CI: 1.164-10.295,
p=0.026) even when the analysis was restricted
to those patients with available data for HIV-RNA
at LPV/r start and for the calculation of the de-
tectability ratio (Table 2 - Model 2). In this mod-
el, virological rebound was more likely among
patients with HIV-RNA values at LPV/r start
above 30000 copies/mL compared to those with
HIV-RNA values at LPV/r start ≤30000 copies/mL
(HR=3.615, 95% CI: 1.499-8.717, p=0.004) as well
as with increasing values of the detectability ra-
tio (HR=12.998 per 1-unit increment, 95% CI:
1.299-130.042, p=0.029). The baseline character-
istics of the patients included or excluded in
Model 2 were compared, and the results of the
comparisons between the two groups are illus-
trated in Table 3. 
Change in CD4+ cell counts from baseline was
similar between patients who switched to ATV
compared to those who switched to an ATV/r-
containing regimen (Absolute change: 50 (-
19/+140) vs 40 (-46/+124) cells/mm3, p=0.222; rel-
ative change: 14% (-5/+38) vs 9% (-10/+34),
p=0.266).
Switch to boosted or unboosted atazanavir 245
TAbLE 3 - Baseline characteristics according to inclusion in the two models of multivariable analysis.
Patients not included Patients included in P-value P-value
in Multivariable model 2 Multivariable model 2 (for patients (for patients
(N=295) (N=158) treated with treated with
ATV/r (n=257) ATV (n=38) ATV/r (n=115) ATV (n=43) ATV/r) ATV)
Age (years) [median (IQR)] 44 (40 – 50) 44 (40 - 49) 46 (43 – 50) 44 (41 – 49) 0.104 0.646
Males [n (%)] 194 (76%) 25 (66%) 86 (75%) 32 (74%) 0.897 0.468
Previous AIDS diagnosis [n (%)] 79 (31%) 12 (32%) 30 (26%) 13 (30%) 0.390 0.999
HCVAb+ [n (%)] 43 (38%) 11 (48%) 37 (36%) 15 (38%) 0.780 0.440
HbsAg+ [n (%)] 11 (10%) 1 (5%) 5 (5%) 2 (5%) 0.197 0.999
Nadir CD4+ [median (IQR)] 136 (44-222) 191 (84-250) 196 (100-311) 163 (95-248) <0.0001 0.970
CD4+/µL [median (IQR)] 429 (300-602) 408 (273-509) 473 (346-670) 394 (268-575) 0.028 0.969
Duration of LPV/r (days) 515 (324-871) 558 (238-805) 548 (336-952) 456 (238-731) 0.253 0.557
[median (IQR)]
Change in nucleoside 151 (59%) 20 (53%) 40 (35%) 11 (26%) <0.0001 0.021
analogues in the regimen 
at switch to ATV [n (%)]
Use of tenofovir with ATV 169 (66%) 7 (18%) 68 (59%) 13 (30%) 0.244 0.303
[n (%)]
Use of thymidine analogues 34 (13%) 11 (29%) 20 (17%) 19 (44%) 0.339 0.174
with ATV [n (%)]
Total cholesterol (mg/dL) 205 (168-241) 218 (180-262) 221 (188-258) 218 (167-242) 0.021 0.718
[median (IQR)]
Triglycerides (mg/dL) 219 (136-338) 196 (152-305) 214 (146-326) 204 (138-491) 0.890 0.654
[median (IQR)]
Glucose [median (IQR)] 95 (84-100) 89 (82-100) 88 (78-102) 86 (80-98) 0.035 0.531
ATV: unboosted atazanavir; ATV/r: boosted atazanavir; LPV/r: lopinavir/ritonavir.
Change in CD4+ cell counts was also evaluated
according to the use of tenofovir, the use of
thymidine analogues or the HIV-RNA level at
LPV/r start but none of these characteristics
showed significant differences (data not shown).
At the end of follow-up no significant differences
in lipidic and glucidic changes from baseline were
found between the two groups (Total cholesterol:
ATV=-31 (-51/-11), ATV/r=-24 (-49/-2), p=0.193;
Triglycerides: ATV=-69 (-136/-14), ATV/r=-55 
(-143/0), p=0.450; Glucose: ATV=0 (-8/+7),
ATV/r=+1(-10/+10), p=0.580). However, when
changes with regard to the National Cholesterol
Education Programme (NCEP) normality thresh-
olds were analyzed, several differences were found.
Abnormal values of triglycerides were observed at
baseline in 260/361 (72%) of patients switched to
ATV/r and in 57/81 (70.4%) of those switched to
ATV (comparison between the two groups:
p=0.786). At the end of follow-up, these propor-
tions decreased to 52.7% (175/332) and 36%
(27/75), respectively (comparison between the two
groups: p=0.010). A normalization of triglyceride
levels at the end of follow-up was observed in
75/231 (32.5%) and in 26/49 (53.1%) of patients
with abnormal levels at baseline and switched, re-
spectively, to ATV/r and ATV (p=0.008).
Abnormal values of total cholesterol were ob-
served at baseline and at the end of treatment,
respectively, in 211/362 (58.3%) and 135/339
(39.8%) in patients switched to ATV/r, and in
50/82 (61%) and 22/78 (28.2%) in those switched
to ATV (comparison between the two groups: at
baseline: p=0.710; at the end of follow-up:
p=0.069). A normalization of total cholesterol lev-
els at the end of follow-up was observed in 74/189
(39.2%) and in 27/45 (60%) of patients with ab-
normal levels at baseline who switched to ATV/r
and ATV, respectively (p=0.012).
Abnormal values of glucose (≥100 mg/l) were ob-
served at baseline and at the end of treatment,
respectively, in 66/360 (18.3%) and 85/346
(24.6%) in patients switched to ATV/r, and in
15/81 (18.5%) and 14/83 (16.9%) in those
switched to ATV (comparison between the two
groups: at baseline: p=0.999; at the end of follow-
up: p=0.149). A normalization of glucose levels
at the end of follow-up was observed in 29/66
(43.9%) and in 8/14 (57%) of patients with ab-
normal levels at baseline who switched to ATV/r
and ATV, respectively (p=0.394).
DISCUSSION
Simplification of complex, PI - based regimens
with simpler, non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) - based (barreiro et al.,
2000; Dieleman et al., 2002; bucher et al., 2003;
Molina et al., 2005) or a triple nucleoside-based
regimens (Clumeck et al., 2001; Katlama et al.,
2003) has been advocated as a strategy to im-
prove patient compliance and has been associ-
ated with comparable or even improved control
of viral replication as compared with continu-
ing the current PI. However, this strategy is not
always feasible because of hypersensitivity, con-
traindications, or resistance to these drugs; in
these cases, a switch within the PI class can be
pursued, in particular when it can also improve
the patients’ metabolic profile. In a randomized
clinical trial of antiretroviral naïve patients,
ATV/r and ATV showed partially different effects
on blood lipid levels, with more patients in the
ATV/r than in the ATV arm (30% vs 18%) shift-
ing upward by at least one NCEP category in
fasting triglycerides. On the contrary, no be-
tween-groups differences were observed with re-
gard to cholesterol levels and virological re-
sponse (Malan et al., 2008). In this retrospective
observational analysis of patients switching from
a virologically-controlled LPV/r regimen to
boosted or unboosted ATV, we found a virolog-
ical rebound rate of 16.7% after a median of 547
days follow-up, with no differences in virological
rebound or in changes in CD4+ cell counts ac-
cording to the presence of boosting or not. Our
findings are consistent with those observed in a
large retrospective study not specifically focused
on LPV/r switch (Pavie et al., 2011) and those
observed in a prospective randomized study fo-
cused on switch from ATV/r to ATV in naïve pa-
tients (Ghosn et al., 2010). Interestingly, although
the use of unboosted atazanavir with TDF has
not been tested in clinical trials and is not cur-
rently recommended because of the risk of sub-
optimal ATV pharmacokinetics, we did not find
an increased risk of virological failure in patients
using this combination. On the contrary, use of
timidine analogues was an independent predic-
tor of virological failure, possibly reflecting the
impact of NRTI archived mutations in favour-
ing the virological rebound in patients largely
pretreated. 
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In our opinion, the most interesting finding is
that patients who started the LPV/r-containing
regimen with >30000 copies/mL had a higher
likelihood of experiencing virological rebound, in
particular those who were switched to ATV.
Furthermore, the risk of virological failure after
simplification increased with higher viral load
levels at the start of treatment with LPV/r.
Although we did not have a control group, this
finding might discourage the switch from LPV/r
to ATV, and particularly to ATV, in patients who
started LPV/r with >30000 copies HIV-RNA/ml.
In general, we observed an improvement in the
lipid profile and, in particular, we found some
differences between the two groups: more pa-
tients among those switched to ATV reached nor-
mal values of triglycerides and cholesterol. The
differences between the two groups in lipid and
immunological changes were consistent with the
results from naïve patients randomized to receive
ATV or ATV/r, both with extended-release stavu-
dine and lamivudine, in the clinical trial previ-
ously mentioned (Malan et al., 2008).
Other studies investigated the safety of switching
from other PI- to ATV-based regimens; none of
these studies investigated whether switching from
LPV/r to ATV/r or ATV leads to different out-
comes. In the ATAZIP Study 248 patients with
less than three failures to PI-containing regimens,
less than five PI resistance mutations, and unde-
tectable viral load while on a stable LPV/r-con-
taining regimen were randomized 1:1 to change
LPV/r to ATV/r or not. Virological failure after 48
weeks of follow-up were 5% in the ATV/r arm and
6% in the LPV/r arm; patients switched to ATV/r
showed a significant reduction in total choles-
terol and triglycerides at the end of the study
(Mallolas et al., 2007). Virological failures were
slightly higher (11% in the ATV/r and 13% in the
LPV/r arm) in a sub-analysis restricted to patients
with a history of virological failure on PIs or with
HIV mutations associated with PI resistance
(Podzamczer et al., 2007).
Our results are not directly comparable with
those from the ATAZIP study. Our virological re-
bound rates are slightly higher, but this differ-
ence might be explained by the difference in study
design. Glucose levels did not change after switch
in either group in line with previous findings
(Guffanti et al., 2007), but in the present study in-
sulin and oral glucose tolerance tests were not
performed to assess for changes in insulin sensi-
tivity.
The present study has several limitations. Patients
who interrupted ATV without having at least one
follow-up visit and CD4 and viral load while still
on-drug were excluded from the analysis.
Moreover, data on previous virological failures
and drug resistance were available for a minori-
ty of patients. So it is possible that patients with
more virological failures before the start of LPV/r
were preferentially switched to ATV/r rather than
to ATV. This may represent a confounder by in-
dication that has not been completely controlled
in the analysis. In an attempt to correct for this
bias, when data were available, we calculated the
detectability ratio as an indirect tool to measure
previous virological failures, but it did not prove
to be predictive of virological rebound in a second
multivariable model. The switch to an ATV-con-
taining regimen was associated with a significant
reduction in the normalized-for-age cardiovas-
cular risk score (Colafigli et al., 2008). As we could
not calculate the cardiovascular risk score for all
patients, because some cardiovascular risk fac-
tors were not reported in the clinical records of
some patients, we were not able to assess if the
switch to ATV reduced the cardiovascular risk
score more than the switch to ATV/r. Finally,
samples for lipid and glucose were drawn without
absolute certainty of the fasting state of the pa-
tient, and information on changes in concomi-
tant medications (including lipid-lowering agents)
were not available for all of the patients; such
changes could have affected the results.
Nevertheless, the follow-up of our patients was
much longer than that of other studies (78 vs. 48
weeks) and we studied patients with a median ex-
posure to LPV/r of 520 days. 
In conclusion, our study provides some useful in-
formation on switches within the PI class: re-
placing LPV/r with ATV (boosted or unboosted)
yielded a similar rate of virological rebound at
one-year follow-up. Viral load at the initiation of
LPV/r may be useful in driving the choice be-
tween boosted or unboosted ATV. We suggest
that in patients virologically suppressed while re-
ceiving a combination of drugs including LPV/r,
a switch to an ATV regimen could be preferen-
tially offered to patients who started LPV/r with
a relatively low viral load: in these conditions
switching to an ATV-based regimen does not
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seem to favour virological failure as compared to
a switch to an ATV/r-based antiretroviral combi-
nation, and it is associated with a more frequent
normalization of total cholesterol and triglyceride
levels.
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